Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.80 |
| ▸ | HPGD | P15428 | 4/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.62 |
| ▸ | CNR1 | P21554 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2677030 | 0.89 | ATM (1.00) | ATMHPGDGAATRPV1CNR1 | |
| SCHEMBL9827968 | 0.87 | ATM (0.90) | ATMHPGDGAATRPV1CNR1 | |
| SCHEMBL5656019 | 0.86 | ATM (0.87) | ATMHPGDGAATRPV1CNR1 | |
| SCHEMBL6349089 | 0.86 | ATM (0.87) | ATMHPGDGAATRPV1CNR1 | |
| SCHEMBL5842518 | 0.85 | ATM (0.65) | ATMHPGDGAATRPV1CNR1 | |
| SCHEMBL27330601 | 0.85 | ATM (0.65) | ATMHPGDGAATRPV1CNR1 | |
| SCHEMBL3199912 | 0.85 | ATM (0.60) | ATMHPGDGAATRPV1CNR1 | |
| SCHEMBL10585628 | 0.84 | TRPV1 (0.83) | ATMHPGDGAATRPV1CNR1 | |
| SCHEMBL8277246 | 0.84 | ATM (0.58) | ATMHPGDGAATRPV1CNR1 | |
| SCHEMBL3207999 | 0.83 | ATM (0.58) | ATMHPGDGAATRPV1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220221433-A1 | MASS SPECTROMETRY ASSAY METHODS FOR DETECTION OF METABOLITES | METABOLON, INC. | 2022-07-14 | — | — | US | claimed |
| EP-3977112-A1 | MASS SPECTROMETRY ASSAY METHODS FOR DETECTION OF METABOLITES | Metabolon Inc. (US) | 2022-04-06 | — | — | EP | claimed |
| CN-113892029-A | Mass spectrometry method for detecting metabolites | 梅塔博隆股份有限公司 | 2022-01-04 | — | — | CN | claimed |
| WO-2020242744-A1 | MASS SPECTROMETRY ASSAY METHODS FOR DETECTION OF METABOLITES | METABOLON, INC. (US) | 2020-12-03 | — | — | WO | claimed |
| EP-1880711-B1 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO CO LTD (JP) | 2016-07-20 | — | — | EP | claimed |
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | claimed |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | SHISEIDO COMPANY, LTD. (JP) | 2012-09-13 | — | — | US | claimed |
| EP-1880711-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-01-23 | — | — | EP | claimed |
| US-20030065175-A1 | Novel heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION | 2003-04-03 | — | — | US | claimed |
| WO-1998046599-A1 | NOVEL CARBOXAMIDES AS PLATELET AGGREGATION INHIBITORS | J. URIACH & CIA. S.A. (ES) | 1998-10-22 | — | — | WO | claimed |
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-11667645-B2 | Granzyme B directed imaging and therapy | CYTOSITE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20220221433-A1 | MASS SPECTROMETRY ASSAY METHODS FOR DETECTION OF METABOLITES | METABOLON, INC. | 2022-07-14 | — | — | US | disclosed |
| EP-3977112-A1 | MASS SPECTROMETRY ASSAY METHODS FOR DETECTION OF METABOLITES | Metabolon Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-113892029-A | Mass spectrometry method for detecting metabolites | 梅塔博隆股份有限公司 | 2022-01-04 | — | — | CN | disclosed |
| WO-1994027969-A1 | ISOQUINOLINETRIONE DERIVATIVES AS HERBICIDES | ZENECA LIMITED (GB) | 1994-12-08 | — | — | WO | disclosed |
| EP-0362002-A1 | HIV protease inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-04-04 | — | — | EP | disclosed |
| EP-0356595-A1 | Novel peptidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-03-07 | — | — | EP | disclosed |
| EP-0275101-A2 | Novel peptidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-07-20 | — | — | EP | disclosed |
| US-4219561-A | ADRENERGIC BLOCKING AGENTS, HYPOTENSIVE, ANTIARRHYTHMIA, ANGINA PECTORIS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | GZMB, PRF1, CTSB | ATM 3998/4885HPGD 1240/4885GAA 64/4885 |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | CUTA, AAAS, NUP160 | ATM 104/4885HPGD 2394/4885GAA 486/4885 |
| US-20030065175-A1 | Novel heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them | MRPL21, Q6ZSR9, ZYX | ATM 4651/4885HPGD 2420/4885GAA 647/4885 |
| US-11667645-B2 | Granzyme B directed imaging and therapy | GZMB, PRF1, CTSB | ATM 3998/4885HPGD 1240/4885GAA 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.